menu search

MCRB / Seres Therapeutics, Inc. (MCRB) Q3 2023 Earnings Call Transcript

Seres Therapeutics, Inc. (MCRB) Q3 2023 Earnings Call Transcript
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q3 2023 Results Conference Call November 2, 2023 8:00 AM ET Company Participants Kevin Mannix - Head, IR Eric Shaff - CEO Dr. Terri Young - Chief Commercial Officer David Arkowitz - CFO Conference Call Participants Joseph Thome - TD Cowen Edward Tenthoff - Piper Sandler Tessa Romero - JPMorgan Jeff Jones - Oppenheimer Keay Nakae - Chardan Stephen Sloan - Goldman Sachs Operator Welcome to the Seres Therapeutics Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded. Read More
Posted: Nov 4 2023, 11:52
Author Name: Seeking Alpha
Views: 022819

MCRB News  

Seres Therapeutics, Inc. (MCRB) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 4, 2023

Seres Therapeutics, Inc. (MCRB) Q3 2023 Earnings Call Transcript

Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q3 2023 Results Conference Call November 2, 2023 8:00 AM ET Company Participants Kevin Mannix - Head, IR Eric more_horizontal

Seres Therapeutics: Approved Drug And Nestle Partnership Make It A Buy

By Seeking Alpha
September 1, 2023

Seres Therapeutics: Approved Drug And Nestle Partnership Make It A Buy

Seres Therapeutics trades near its 52-week low and presents an asymmetric risk-reward profile. The company's lead asset, SER-109, has successfully con more_horizontal

Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates

By Zacks Investment Research
May 9, 2023

Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates

Seres Therapeutics (MCRB) came out with a quarterly loss of $0.57 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.61 more_horizontal

Seres Gets FDA Approval And The Share Price Goes Down!

By Seeking Alpha
May 3, 2023

Seres Gets FDA Approval And The Share Price Goes Down!

Biotech investing is a wild ride but share prices falling after FDA approval, as has just happened to Seres Therapeutics VOWST product, is pretty weir more_horizontal

Strength Seen in Seres Therapeutics (MCRB): Can Its 5.8% Jump Turn into More Strength?

By Zacks Investment Research
April 14, 2023

Strength Seen in Seres Therapeutics (MCRB): Can Its 5.8% Jump Turn into More Strength?

Seres Therapeutics (MCRB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might no more_horizontal

Seres Therapeutics (MCRB) Moves 10.9% Higher: Will This Strength Last?

By Zacks Investment Research
March 22, 2023

Seres Therapeutics (MCRB) Moves 10.9% Higher: Will This Strength Last?

Seres Therapeutics (MCRB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimat more_horizontal

Seres Therapeutics, Inc. (MCRB) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 7, 2023

Seres Therapeutics, Inc. (MCRB) Q4 2022 Earnings Call Transcript

Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET Company Participants Carlo Tanzi - IR Officer Eric S more_horizontal

Seres Therapeutics (MCRB) Reports Q4 Loss, Misses Revenue Estimates

By Zacks Investment Research
March 7, 2023

Seres Therapeutics (MCRB) Reports Q4 Loss, Misses Revenue Estimates

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -31.71% and 89.21%, respectively, for the quarter ended December 2022. Do the nu more_horizontal


Search within

Pages Search Results: